Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag308 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.08.2026. Verfasst von Xuanyi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, New Haven, CT 06510, United States. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Colorectal Neoplasms, Oncogene Proteins, Fusion. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI Mentored Clinical Scientist Research Career Development Award.
Abstract (Originalsprache)
Background
Anaplastic lymphoma kinase (ALK) fusions are established oncogenic drivers and therapeutic targets in multiple malignancies, including non-small cell lung cancer, but are rare in colorectal cancer (CRC). Although ALK fusions in CRC have been associated with sensitivity to ALK inhibitors, their broader genomic context remains incompletely defined. We aimed to characterize the prevalence, clinicogenomic features, and therapeutic implications of ALK fusions in advanced CRC. Materials and Methods Comprehensive genomic profiling using hybrid capture-based next-generation sequencing was performed on 56 206 advanced CRC tumors to identify alterations, including ALK fusions. Microsatellite instability (MSI)/mismatch repair (MMR) status, tumor mutational burden (TMB), genomic ancestry, COSMIC trinucleotide signatures, and homologous recombination deficiency (HRD) signatures were derived from sequencing data. PD-L1 expression was assessed by immunohistochemistry.
Results
ALK fusions were identified in 63 tumors (0.1%). Compared with ALK fusion-negative CRC, ALK fusion-positive (ALKfus+) tumors demonstrated enrichment for MSI-high/MMR-deficient status and high TMB, with numerically higher PD-L1 expression. In contrast, canonical CRC driver alterations were markedly depleted, including KRAS, APC, and PIK3CA mutations.
Conclusions
ALK fusions define a rare but biologically distinct subset of CRC characterized by frequent MSI-high/MMR-deficient status and a unique genomic landscape. These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale Cancer Center, New Haven, CT 06510, United States.
- Dana-Farber Cancer Institute, Boston, MA 02215, United States.
- Foundation Medicine, Inc, Boston, MA 02210, United States.
- Upstate Medical UniversitySyracuse, NY 13210, United States.
ORCID-Profile: Xuanyi Li, Dean C Pavlick, Michael Cecchini
Förderung
- NCI NIH HHS
- NCI Mentored Clinical Scientist Research Career Development Award
Zitieren
APA
Li, X., Yasin, F., Pavlick, D. C., Ross, J. S., & Cecchini, M. (2026). Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag308
Vancouver
Li X, Yasin F, Pavlick DC, Ross JS, Cecchini M. Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag308
BibTeX
@article{Li2026,
author = {Li, Xuanyi and Yasin, Faiza and Pavlick, Dean C and Ross, Jeffrey S and Cecchini, Michael},
title = {Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag308}
}
EUVIMED